This website is intended for individuals living with relapsed/refractory multiple myeloma in United States.

Investigating the effectiveness and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared to pomalidomide in combination with bortezomib and dexamethasone (bor/dex) for treatment of relapsed/refractory multiple myeloma

If you have multiple myeloma that has come back after you completed treatment (relapsed) or progressed despite active treatment (refractory), a research study like dreaMM8 could be an appropriate part of your treatment plan, depending on your specific circumstances. As always, it is best to discuss a research study with your doctor so he or she can help you decide if this study may be appropriate for you.